MONDAY, MARCH 22
Welcoming Remarks and Keynote Session (Joint) (8am Denver/Mountain Time Start)
*Jay D. Horton, University of Texas Southwestern Medical Center, USA
*Alphonse E. Sirica, Virginia Commonwealth University, USA
Helen H. Hobbs, University of Texas Southwestern Medical Center, USA
PNPLA3's Role in NAFLD
Hashem B. El-Serag, Baylor College of Medicine, USA
Changing Epidemiological Trends in Non-Alcoholic Fatty Liver Disease versus Viral-Associated Hepatobiliary Cancers

Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fibrogenesis in the Pathogenesis of Hepatobiliary Cancers (Joint) (9:10am Denver/Mountain Time Start)
*Jay D. Horton, University of Texas Southwestern Medical Center, USA
*Alphonse E. Sirica, Virginia Commonwealth University, USA
Lopa Mishra, George Washington University, USA
TGF-beta Signaling in Liver Fibrosis and Hepatocellular Carcinoma
Maria Rescigno, Humanitas University, Italy
The Gut-Liver Axis in Liver Cancer Risk Conditions
Daniel A. Heller, Memorial Sloan Kettering Cancer Center, USA
Lipid Dysregulation in Inflammation, NASH, and Cancer
Juan R. Sanabria, Marshall University/Case Western Reserve University, USA
Short Talk: The α1-Na/K-ATPase/Src-p/PI3K Pathway Modulates the Survivin-SMAC Apoptotic "Switch" in NASH Related Hepatocellular Carcinoma: A Translational Study

Career Roundtable (Joint) (12:30pm Denver/Mountain Time Start)
Poster Session 1 (Joint) (2pm Denver/Mountain Time Start)

Tumor Microenvironment and Hepatobiliary Cancers (3pm Denver/Mountain Time Start) (EK29)
*Lopa Mishra, George Washington University, USA
Silvia Affo, Columbia University, USA
Role of Cancer Associated Fibroblasts in Cholangiocarcinoma
Amalia Lujambio, Icahn School of Medicine at Mount Sinai, USA
Mechanisms of Immune Escape in Hepatocellular Carcinoma
Alphonse E. Sirica, Virginia Commonwealth University, USA
The Desmoplastic Reaction and Intrahepatic Cholangiocarcinoma Progression: CAFs, Select Molecular Drivers, and Prognostic Implications

*Gregory J. Gores, Mayo Clinic, USA
Targeting the Tumor Microenvironment for Cholangiocarcinoma Therapy
Yuhua Xue, University of Pittsburgh, USA
Short Talk: p-Ezrin (Thr567) Synergizes with Akt Signaling to Accelerate Yap Mediated Cholangiocarcinogenesis but Correlates with a Favorable Prognosis in Human Intrahepatic Cholangiocarcinoma (ICC) Patients

Genetics of NAFLD (3pm Denver/Mountain Time Start) (EK28)
*Jay D. Horton, University of Texas Southwestern Medical Center, USA
Elizabeth K. Speliotes, University of Michigan, USA
Use of GWAS to Identify SNPs Associated with NAFLD
*Henry N. Ginsberg, Columbia University Vagelos College of Physicians and Surgeons, USA
Noura S. Abul-Husn, Icahn School of Medicine at Mount Sinai, USA
Genomics and Liver Disease in Diverse Populations: From Biobanks to Patients

KEYSTONE SYMPOSIA
on Molecular and Cellular Biology
Hepatobiliary Cancers: Pathobiology and Translational Advances (EK29)
Scientific Organizers: Alphonse E. Sirica, Gregory J. Gores and Lopa Mishra
Supported by the Directors' Fund
Fatty Liver Disease and Multi-System Complications (EK28)
Scientific Organizers: Jay D. Horton, Morris J. Birnbaum and Hannele Yki-Järvinen
March 22-24, 2021 • Virtual at your computer
Sponsored by Merck & Co., Inc. and Novo Nordisk A/S

For the most up-to-date details, visit https://www.keystonesymposia.org.
TUESDAY, MARCH 23

Hepatobiliary Cancer Biomarkers and Molecular Subtypes (8am Denver/Mountain Time Start) (EK29)

*Gregory J. Gores, Mayo Clinic, USA
*Alphonse E. Sirica, Virginia Commonwealth University, USA
Yujin Hoshida, UT Southwestern Medical Center, USA
Liver Cancer Risk-Predictive Molecular Biomarkers Specific to Clinico-Epidemiological Contexts
Augusto Villanueva Rodriguez, Icahn School of Medicine at Mount Sinai, USA
Liquid Biopsy in Hepatobiliary Cancers
Jessica Zucman-Rossi, University Paris Descartes-HEGP, France
Mechanisms of Liver Carcinogenesis Define Specific Molecular and Phenotypic HCC Subgroups
Jesper Beje Andersen, University of Copenhagen, Denmark
Defining Distinct Subtypes of Intrahepatic Cholangiocarcinoma by Molecular Profiling: Diagnostic, Prognostic, and Therapeutic Applications
Robert F. Schwabe, Columbia University, USA
Discovery of Subgroup-Specific HCC Master Regulators by Systems Biology Approaches
Kerstin Seidel, Genentech, USA
Short Talk: Notch Inhibition Regresses Progenitor-Like HCCs by Inducing Hepatocyte Differentiation through Controlling C/EBPα Expression and HNF4α Activity
Sunjin Ko, University of Pittsburgh, USA
Short Talk: NOTCH-YAP1/TEAD-DNMT1 Axis Drives Hepatocyte Reprogramming into Intrahepatic Cholangiocarcinoma

Role of Lipids in NAFLD (8am Denver/Mountain Time Start) (EK28)

Mitchell A. Lazar, Perelman School of Medicine, University of Pennsylvania, USA
Circadian Contributions to NAFLD
*Catherine Postic, INSERM Institut Cochin, France
Altered Insulin Signaling and Glucose Toxicity in NAFLD
*Hannele Yki-Järvinen, University of Helsinki, Finland
Effects of Genetic Risk Factors for NAFLD on Hepatic Lipid Metabolism
Eran Elina, Weizmann Institute of Science, Israel
Host Microbiome Interactions in Health and Disease
HongMin Ni, University of Kansas Medical Center, USA
Short Talk: Lack of VMP1 Impairs Hepatic Lipoprotein Secretion and Promotes Nonalcoholic Steatohepatitis in Mice

Joanne Hsieh, Columbia University, USA
Short Talk: Sexually Dimorphic Mechanisms of Action of TTC39B in Hepatic Lipogenic Gene Expression
Xiao-Wei Chen, Peking University, China
Short Talk: An ER Lipid Scramblase (ELS) Safeguards Lipoprotein Biogenesis and Lipid Homeostasis
Zhao Yue Zhang, Princeton University, USA
Short Talk: Sirtine Catabolism Generates NADPH to Support Hepatic Lipogenesis

Meet the Editors (Joint) (12:30pm Denver/Mountain Time Start)
Poster Session 2 (Joint) (2pm Denver/Mountain Time Start)

Genomics, Molecular Heterogeneity, and Precision Medicine in Hepatobiliary Cancers (3pm Denver/Mountain Time Start) (EK29)

*Lopa Mishra, George Washington University, USA
*Alphonse E. Sirica, Virginia Commonwealth University, USA
Irene Oi Lin Ng, University of Hong Kong, Hong Kong
Molecular Biomarkers in Hepatocellular Carcinoma
Xin Wei Wang, NCI, National Institutes of Health, USA
Causes and Functional Intricacies of Intertumor and Intratumor Heterogeneity in Primary Hepatobiliary Cancers
Renemathy Dhanasekaran, Stanford University, USA
Complexities of Genetic Heterogeneity in Hepatocellular Carcinoma
Teh Bin Tean, Duke-NUS Medical School, Singapore
Genomic and Epigenomic Studies of Cholangiocarcinoma and their Clinical Implications
Josep Llovet, Icahn School of Medicine at Mount Sinai, USA
Immune Therapies for HCC: is NASH-HCC Responding Different
Bangyan Stiles, University of Southern California, USA
Short Talk: Heterogeneous Liver Cancer Development Promoted by PTEN Regulated beta-Catenin and SOX9 Signal
Chungui Xu, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospi, China
Short Talk: Gender Distinct in Genomic Features of HBV-Related Hepatocellular Carcinoma

Pathways to NASH (3pm Denver/Mountain Time Start) (EK28)

*Morris J. Birnbaum, Pfizer Inc., USA
Mark A. McNiven, Mayo Clinic, USA
Lipid Droplet Formation and Lipophagy in Fatty Liver Disease
*Tobias C. Walther, Harvard School of Public Health, USA
Lipid Droplet Biology in NAFLD
Annelise Poss, University of Utah, USA
Short Talk: Ceramides as Mediators of Endoplasmic Reticulum Stress in NASH

Cholsoon Jang, University of California, Irvine, USA
Short Talk: The Small Intestine Shields the Liver from Fructose-Induced Steatosis

Kahealani Uehara, University of Pennsylvania, USA
Short Talk: Activation of Hepatic mTORC1 Protects Against NASH via Dual Regulation of VLDL- TAG Secretion and De Novo Lipogenesis

Sabine Daemen, Washington University in St. Louis, USA
Short Talk: The Hepatic Crown-like Structure in NASH: A Nexus between Monocyte-Derived Macrophages, Hepatic Stellate Cells, and Tissue Fibrosis

Samar Ibrahim, Mayo Clinic, USA
Short Talk: Lipid-Induced Endothelial Vascular Cell Adhesion Molecule 1 Promotes Nonalcoholic Steatohepatitis Pathogenesis

Wenke Jonas, German Institute of Human Nutrition, Germany
Short Talk: Immunity-Related GTPase IFGGA2 Induces Degradation of Hepatic Lipids by Lipophagy

Man Hsin Hung, NCI, National Institutes of Health, USA
Short Talk: Tumor Methionine Metabolism Drives T-Cell Exhaustion in Hepatocellular Carcinoma

Andreas Prokesch, Medical University Graz, Austria
Short Talk: Overcoming HCC Drug Resistance by Targeting Metabolic Flexibility Conferred by p53

Emerging Therapies for NASH (8am Denver/Mountain Time Start) (EK28)

*Hannele Yki-Järvinen, University of Helsinki, Finland
*Morris J. Birnbaum, Pfizer Inc., USA
DGAT2 Inhibition for NASH

Chuhan Chung, Gilead Sciences, USA
Combination Therapies for NASH Cirrhosis

Greg Steinberg, McMaster University, Canada
Role of ATP Citrate Lyase (ACLY) in NASH and HCC

Kendra K. Bence, Pfizer Inc., USA
Inhibition of Fructose Metabolism for the Treatment of NAFLD

Lei Ling, NGM Biopharmaceuticals, USA
Therapeutic FGF19 in Non-Alcoholic Steatohepatitis

Aimee L. Edinger, University of California, Irvine, USA
Short Talk: A Drug-Like Sphingolipid Opposes Mitochondrial Fragmentation and Corrects the Metabolic Sequelae of Obesity

Brian Rady, Janssen R&D, USA
Short Talk: Inhibition of Hepatocyte Inflammasome Improves Features of NASH in foz/foz Mice

Haressh Sajiir, University of Queensland - Mater Research Institute, Australia
Short Talk: Development of Liver-Targeted Interleukin-22 for Fatty Liver Disease

Madhulika Tripathi, Duke-NUS Medical School Singapore, Singapore
Short Talk: HHcy is a Feature and Mediator of NASH that Permits B12 and Folate to be an Effective Therapy for NASH

Closing Remarks (10:50am Denver/Mountain Time Start) (EK29)

Closing Remarks (10:50am Denver/Mountain Time Start) (EK28)